HUYA Development Compounds

HUYA Bioscience International identifies a select subset of promising early stage compounds from its product portfolio and positions them for development in markets worldwide. HUYA seeks opportunities in therapeutic areas with significant market potential and unmet medical need, where the compound has a competitive advantage, strong patent position worldwide, and a clear clinical development path.

HUYA performs preliminary diligence on many drug candidates to find the most promising opportunities that would benefit from added value. The company is currently working with a number of compounds including the next generation oncology drug HBI-8000, the novel anti-arrhythmic HBI-3000, and the small molecule with regenerative properties for myocardial infarction HBI-3802.

About HBI-8000

HBI-8000 is a novel, oral inhibitor of histone deacetylases (HDAC). HDAC inhibitors work by controlling how tightly DNA is wound around histone proteins. By deacetylating (removing an acetyl group from) histones, HDACs appear to promote tighter winding of DNA around these proteins, leading to reduced access by gene transcription factors. This results in decreased expression of proteins involved in cell differentiation, cell cycle arrest, tumor immunity, angiogenesis, drug resistance, and apoptotic elimination of damaged cells, all of which contribute to the development and progression of cancer.

Although significant preclinical and clinical activity has been observed with HDAC inhibitors, most have characteristics which limit their potential for clinical success or broad applicability. In contrast, HBI-8000 is a next generation HDAC inhibitor with proven efficacy and safety in lymphomas and, due to its superior properties, the potential for use as a stand-alone therapeutic as well as in combination with a wide variety of marketed anti-tumor agents.

About HBI-3000

HBI-3000 is a multi-ion channel blocker in development for the treatment of arrhythmia. Anti-arrhythmic drugs are used today to treat patients with atrial fibrillation (AF), a serious condition that afflicts more than 30 million worldwide. There is a significant need for safer and more effective pharmacological interventions to treat arrhythmia. Anti-arrhythmic agents have also been used for the treatment of ventricular arrhythmias, although most have failed to demonstrate a survival advantage, and in some cases they carry significant safety risk.

HBI-3000 has a unique ion channel profile (Ito, fast and slow Na, IKr, and L-Ca) and is devoid of pro-arrhythmic risk in “gold standard” preclinical models. Its pre-clinical pharmacology also supports the potential of HBI-3000 to restore sinus rhythm in cases of atrial fibrillation. This profile makes HBI-3000 one of the most promising antiarrhythmics currently under development.

About HBI-3802

HBI-3802 is a small molecule with remarkable preclinical activity to improve heart function. Coronary disease is the leading cause of death in the US and most industrialized countries. Treatment of patients after a myocardial infarction, or heart attack, involves drugs to improve blood flow and other symptomatic interventions. However, no therapy in current development appears adequate to improve heart function itself to a clinically significant extent.

In animal models simulating a myocardial infarction, HBI-3802 stimulates cardiac stem cell differentiation into functional cardiomyocytes, replacing and remodeling dead myocardium with new functional tissue even if treatment was started several days after the heart damage. This potentially revolutionary agent has several promising uses including treatment of the consequences of myocardial infarction (MI), improving global heart function and preventing chronic heart failure (CHF).